Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583782 | 1.00 | RXFP1 (0.35) | RXFP1SIRT2IDH1GAAATM | |
| SCHEMBL3303451 | 0.91 | NPSR1 (0.35) | RXFP1SIRT2IDH1GAAMRGPRX4 | |
| SCHEMBL15310375 | 0.91 | NPSR1 (0.35) | RXFP1SIRT2IDH1GAAMRGPRX4 | |
| SCHEMBL3581027 | 0.90 | SIRT2 (0.33) | RXFP1SIRT2GAAATML3MBTL1 | |
| SCHEMBL3581023 | 0.90 | SIRT2 (0.33) | RXFP1SIRT2GAAATML3MBTL1 | |
| SCHEMBL3303434 | 0.87 | S1PR1 (0.35) | RXFP1SIRT2IDH1GAAATM | |
| SCHEMBL3303426 | 0.87 | S1PR1 (0.35) | RXFP1SIRT2IDH1GAAATM | |
| SCHEMBL3299918 | 0.85 | S1PR1 (0.37) | RXFP1SIRT2IDH1ATML3MBTL1 | |
| SCHEMBL3302985 | 0.85 | S1PR1 (0.37) | RXFP1SIRT2IDH1ATML3MBTL1 | |
| SCHEMBL1562448 | 0.85 | S1PR1 (0.37) | RXFP1SIRT2IDH1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273748-B2 | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8232319-B2 | Amino phosphate derivative and S1P receptor modulator having same as an active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100010000-A1 | AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325907-A1 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT | S1PR1, S1PR2, S1PR5 | RXFP1 393/4885SIRT2 2716/4885IDH1 4564/4885 |
| US-20100010000-A1 | AMINO ALCOHOL DERIVATIVE AND IMMUNOSUPPRESIVE AGENT HAVING SAME AS AN ACTIVE INGREDIENT | ALDH7A1, AADAT, IDO1 | RXFP1 4647/4885SIRT2 2251/4885IDH1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.